Mast Cell Immune Regulation in Allergic Responses

Mast cells are tissue-resident immune sentinels best known for their central role in type I hypersensitivity and allergic inflammation. They express high-affinity receptors for immunoglobulin E (IgE), and antigen-mediated cross-linking of these receptors triggers rapid degranulation and the release of histamine, proteases and lipid mediators. This immediate reaction is followed by de novo synthesis of cytokines and chemokines that amplify local inflammation and recruit additional effector cells. To prevent excessive tissue damage and chronic pathology, mast cells are equipped with counter-regulatory receptors and signalling modules that attenuate activation. Among these, inhibitory immunoglobulin superfamily receptors, such as CD300f, recruit phosphatases to immunoreceptor tyrosine-based inhibitory motifs and impose a braking signal on FcεRI-driven cascades. Lipid ligands, including ceramide species, engage CD300 family members to fine-tune mast cell output. The balance between activating and inhibitory inputs is critical not only for determining the severity of allergic manifestations but also for guiding the resolution phase and the restoration of tissue homeostasis. A deeper understanding of the molecular checks on mast cell activity has opened avenues for novel therapies aimed at reinforcing inhibitory pathways or blocking dysregulated activation in asthma, rhinitis and other allergic diseases.

Research from Nature Portfolio

Recent studies have demonstrated that targeted delivery of ceramide­-containing liposomes to the nasal mucosa can engage CD300f on mast cells and suppress the effector phase of allergic rhinitis. In murine models sensitised to ragweed pollen, deficiency of CD300f led to exaggerated sneezing responses, elevated numbers of degranulated mast cells and enhanced eosinophil influx in nasal tissues. By contrast, intranasal administration of ceramide liposomes significantly reduced sneezing frequency, mast cell degranulation and eosinophilic inflammation, indicating that the CD300f–ceramide axis represents a highly selective checkpoint that curtails IgE-driven mucosal allergy. This approach highlights the translational potential of lipid-based therapeutics to reinforce endogenous inhibitory circuits in mast cells and offers a promising strategy for localised control of allergic symptoms without broad immunosuppression.

Mast Cell Immune Regulation in Allergic Responses publication trend

The graph below shows the total number of articles in mast cell immune regulation in allergic responses across all publications each year (not limited to Nature Index journals).

Technical terms

Mast cell: A granulated tissue-resident immune cell that expresses FcεRI and mediates immediate hypersensitivity through degranulation and mediator release.

Degranulation: The rapid exocytosis of preformed granule contents, including histamine and proteases, in response to receptor stimulation.

Immunoglobulin E (IgE): A class of antibody that binds high-affinity receptors on mast cells and basophils and triggers allergic reactions upon antigen cross-linking.

CD300f receptor: An inhibitory immunoglobulin-like receptor on mast cells that contains immunoreceptor tyrosine-based inhibitory motifs and recruits phosphatases to dampen activation.

Ceramide: A bioactive sphingolipid ligand for CD300 receptors that modulates mast cell signalling by engaging inhibitory pathways.

References

1. Intranasal administration of ceramide liposome suppresses allergic rhinitis by targeting CD300f in murine models. Scientific Reports (2024).
2. Ceramide-CD300f Binding Inhibits Lipopolysaccharide-induced Skin Inflammation*. Journal of Biological Chemistry (2017).
3. CD300 Heterocomplexes, a New and Family-restricted Mechanism for Myeloid Cell Signaling Regulation*. Journal of Biological Chemistry (2010).
4. Human CD300C Delivers an Fc Receptor-γ-dependent Activating Signal in Mast Cells and Monocytes and Differs from CD300A in Ligand Recognition*. Journal of Biological Chemistry (2013).